Breaking News Instant updates and real-time market news.

As previously reported, Morgan Stanley downgraded Clorox to Underweight from Equal Weight and cut its price target to $116 from $128. Analyst Dara Mohsenian said valuation looks "stretched" on muted earnings growth and lowered his FY19 earnings estimate by 2% to reflect deterioration in US Household Products sector.

02

May

30

May

CLXClorox

$126.71

-0.09 (-0.07%)

04/19/18

MSCO

04/19/18DOWNGRADEMSCOUnderweight

Clorox downgraded to Underweight from Equal Weight at Morgan Stanley

03/29/18

BMOC

03/29/18NO CHANGETarget $147BMOCOutperform

Clorox on track to meet sales objectives, says BMO Capital

BMO Capital analyst Shannon Coyne writes that the recent meetings with the management team of Clorox gave her more confidence in the company's track to meet its FY18 sales growth targets. Over the longer term, the analyst sees Clorox's "2020 Strategy" yielding outperformance in sales and margins through "continued strong brand investment, innovation and technology transformation". Coyne keeps her Outperform rating and $147 price target on Clorox.

02/08/18

02/08/18DOWNGRADE

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Clorox (CLX) downgraded to Hold from Buy at Argus with analyst John Staszak saying that while the company is benefiting from low-cost operations and strong market share, margin pressure and private-label competition pose obstacles to its growth. 2. Cosan (CZZ) downgraded to Neutral from Buy at UBS. 3. Inphi (IPHI) downgraded to Underperform from Neutral at BofA/Merrill with analyst Vivek Arya citing "materially worse" first quarter guidance led by persistent inventory issues in the coherent transimpedance amplifier/driver business in China. 4. Enanta (ENTA) downgraded to Neutral from Overweight at JPMorgan with analyst Jessica Fye saying she believes improved hepatitis C virus royalties and a lower U.S. tax rate are now reflected in the shares. 5. Allison Transmission (ALSN) downgraded to Neutral from Buy at BofA/Merrill with analyst Ross Gilardi saying he expects a strong fourth quarter driven by robust growth in its high margin spare parts business and a recovery in its Off-Highway segment but sees some risks to operating leverage next year due to business mix and higher R&D. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

02/08/18

ARGS

02/08/18DOWNGRADEARGSHold

Clorox downgraded to Hold at Argus on competitive and margin pressure

As reported earlier, Argus analyst John Staszak downgraded Clorox to Hold from Buy, saying that while the company is benefiting from low-cost operations and strong market share, margin pressure and private-label competition pose obstacles to its growth. The analyst sees few near-term catalysts for the stock after its latest Q2 earnings beat and FY18 guidance raise. Staszak also notes that Clorox has "substantial debt", and investors may sell on any sign that the company could reduce its dividend payment to boost its balance sheet.